32P Atezolizumab plus albumin paclitaxel-based regimens is an optional treatment for EGFR-mutant patients with SCLC transformation after EGFR-TKI
32P Atezolizumab plus albumin paclitaxel-based regimens is an optional treatment for EGFR-mutant patients with SCLC transformation after EGFR-TKI is a paper indexed in ScholarIQ from OpenAlex.
How many citations does 32P Atezolizumab plus albumin paclitaxel-based regimens is an optional treatment for EGFR-mutant patients with SCLC transformation after EGFR-TKI have?
32P Atezolizumab plus albumin paclitaxel-based regimens is an optional treatment for EGFR-mutant patients with SCLC transformation after EGFR-TKI has 1 citations in the OpenAlex counts ScholarIQ stores.
When was 32P Atezolizumab plus albumin paclitaxel-based regimens is an optional treatment for EGFR-mutant patients with SCLC transformation after EGFR-TKI published?
32P Atezolizumab plus albumin paclitaxel-based regimens is an optional treatment for EGFR-mutant patients with SCLC transformation after EGFR-TKI has 2023 year in the ScholarIQ index.
What is the open-access status of 32P Atezolizumab plus albumin paclitaxel-based regimens is an optional treatment for EGFR-mutant patients with SCLC transformation after EGFR-TKI?
32P Atezolizumab plus albumin paclitaxel-based regimens is an optional treatment for EGFR-mutant patients with SCLC transformation after EGFR-TKI has bronze oa status in the ScholarIQ index.
What is the DOI of 32P Atezolizumab plus albumin paclitaxel-based regimens is an optional treatment for EGFR-mutant patients with SCLC transformation after EGFR-TKI?
The DOI for 32P Atezolizumab plus albumin paclitaxel-based regimens is an optional treatment for EGFR-mutant patients with SCLC transformation after EGFR-TKI is on the source record.
What is the OpenAlex record for 32P Atezolizumab plus albumin paclitaxel-based regimens is an optional treatment for EGFR-mutant patients with SCLC transformation after EGFR-TKI?
The OpenAlex for 32P Atezolizumab plus albumin paclitaxel-based regimens is an optional treatment for EGFR-mutant patients with SCLC transformation after EGFR-TKI is on the source record.